Patents by Inventor Jeffrey A. Ledbetter

Jeffrey A. Ledbetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240101982
    Abstract: Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase (e.g., human PON1 or a variant thereof), wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing domain or a domain that specifically binds to the neonatal Fc receptor (FcRn)) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain.
    Type: Application
    Filed: February 17, 2022
    Publication date: March 28, 2024
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Publication number: 20230057085
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Application
    Filed: March 16, 2022
    Publication date: February 23, 2023
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Publication number: 20230024372
    Abstract: Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein.
    Type: Application
    Filed: September 9, 2022
    Publication date: January 26, 2023
    Inventors: Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter
  • Publication number: 20230015291
    Abstract: Compositions and methods relating to DNase fusion polypeptides are disclosed. The fusion polypeptides include a biologically active DNase joined to the amino-terminus of an immunoglobulin Fc region via a flexible polypeptide linker (e.g., a linker containing at least 26 amino acid residues). Typically, the DNase is a hyperactive and/or actin-resistant DNase1 variant (e.g., a variant of human DNase1 having one or more amino acid substitutions selected from substitutions at Asp-53, Tyr-65, Glu-69, Arg-74, Gly-105, and Ala-114 according to amino acid position numbering of mature wild-type human DNase1) or a DNase1L3 variant (e.g., a variant of human DNase1L3 in which the native nuclear localization signals are removed). In some embodiments, the fusion polypeptide includes a polypeptide segment located carboxyl-terminal to the Fc region and which may be, e.g., a biologically active paraoxonase. Also disclosed are dimeric proteins comprising first and second DNase fusion polypeptides as disclosed herein.
    Type: Application
    Filed: August 11, 2022
    Publication date: January 19, 2023
    Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
  • Patent number: 11472864
    Abstract: Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: October 18, 2022
    Assignee: Theripion, Inc.
    Inventors: Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter
  • Patent number: 11306297
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: April 19, 2022
    Assignee: University of Washington
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Publication number: 20220089687
    Abstract: Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein.
    Type: Application
    Filed: December 3, 2021
    Publication date: March 24, 2022
    Inventors: Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter
  • Publication number: 20210395711
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Application
    Filed: May 19, 2021
    Publication date: December 23, 2021
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Patent number: 11034944
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 15, 2021
    Assignee: University of Washington
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Publication number: 20200354447
    Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
    Type: Application
    Filed: December 23, 2019
    Publication date: November 12, 2020
    Inventors: Peter Armstrong THOMPSON, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Laura Sue GROSMAIRE, Robert BADER, William BRADY
  • Publication number: 20190290755
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition; the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: October 26, 2018
    Publication date: September 26, 2019
    Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
  • Patent number: 10307481
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: June 4, 2019
    Assignee: Aptevo Research and Development LLC
    Inventors: Laura S. Grosmaire, Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter A. Thompson, Sandy A. Simon, William Brady
  • Publication number: 20190119660
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 25, 2019
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Patent number: 10202588
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: February 12, 2019
    Assignee: The University of Washington
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Patent number: 10143748
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 4, 2018
    Assignee: Aptevo Research and Development LLC
    Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
  • Publication number: 20180201664
    Abstract: Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 19, 2018
    Inventors: Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter
  • Publication number: 20180187174
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Application
    Filed: August 17, 2017
    Publication date: July 5, 2018
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Patent number: 10000745
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: June 19, 2018
    Assignee: University of Washington
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
  • Publication number: 20180118823
    Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 3, 2018
    Applicant: APTEVO RESEARCH AND DEVELOPMENT LLC
    Inventors: Peter Armstrong THOMPSON, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Laura Sue GROSMAIRE, Robert BADER, William BRADY
  • Patent number: 9790479
    Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: October 17, 2017
    Assignee: University of Washington
    Inventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun